Understanding PLK2: A Potential Drug Target (G10769)

Target Name: PLK2

NCBI ID: G10769

PLK2

Understanding PLK2: A Potential Drug Target

PLK2 (Polo-like kinase 2) is a protein that is expressed in various cell types, including neurons, muscle cells, and cancer cells. It is a serine-thymidine-spikin protein that is involved in cell signaling pathways, including the cAMP/cGMP signaling pathway.

PLK2 has been identified as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these diseases has led to the development of new therapeutic strategies, including inhibitors of PLK2 signaling.

One of the key challenges in studying PLK2 is its complex structure and function. Despite its importance, there is limited understanding of the underlying molecular mechanisms that regulate its activity. Researchers have identified several key components of PLK2 structure and function, including its catalytic active site, which is critical for its catalytic activity.

Additionally, PLK2 has been shown to play a role in regulating cellular processes that are important for its function, including cell growth, differentiation, and survival. For example, studies have shown that PLK2 inhibition can lead to increased cell cycle progression and enhanced sensitivity to chemotherapy drugs.

Despite its potential as a drug target, PLK2 remains a complex and difficult protein to study. Researchers have made significant progress in understanding its structure and function, but much work remains to be done to fully understand its role in cell signaling pathways and its potential as a drug target.

In conclusion, PLK2 is a protein that has significant implications for our understanding of cellular signaling pathways and its potential as a drug target. Further research is needed to fully understand its role in cell signaling pathways and develop new therapeutic strategies for the treatment of various diseases.

Protein Name: Polo Like Kinase 2

Functions: Tumor suppressor serine/threonine-protein kinase involved in synaptic plasticity, centriole duplication and G1/S phase transition. Polo-like kinases act by binding and phosphorylating proteins are that already phosphorylated on a specific motif recognized by the POLO box domains. Phosphorylates CENPJ, NPM1, RAPGEF2, RASGRF1, SNCA, SIPA1L1 and SYNGAP1. Plays a key role in synaptic plasticity and memory by regulating the Ras and Rap protein signaling: required for overactivity-dependent spine remodeling by phosphorylating the Ras activator RASGRF1 and the Rap inhibitor SIPA1L1 leading to their degradation by the proteasome. Conversely, phosphorylates the Rap activator RAPGEF2 and the Ras inhibitor SYNGAP1, promoting their activity. Also regulates synaptic plasticity independently of kinase activity, via its interaction with NSF that disrupts the interaction between NSF and the GRIA2 subunit of AMPARs, leading to a rapid rundown of AMPAR-mediated current that occludes long term depression. Required for procentriole formation and centriole duplication by phosphorylating CENPJ and NPM1, respectively. Its induction by p53/TP53 suggests that it may participate in the mitotic checkpoint following stress

The "PLK2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLK2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets